Latest news and upcoming events

05 May 2021

Cytoki Pharma raises $45 million Series A financing

Upcoming events
  • Bioequity 2021
    17 May – 19 May 2021,

  • Biospain 2021
    29 September – 1 October 2021,
    Pamplona, Spain

Mirum Pharmaceuticals and Vivet Therapeutics enter into exclusive worldwide option and license agreement for Vivet’s gene therapy programs targeting PFIC

Vivet to lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2.

Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting

Overall results support the positive effects of leriglitazone on reducing the progression of cerebral lesions and myelopathy symptoms.

LAVA Therapeutics Announces Pricing of Initial Public Offering

Gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by LAVA, are expected to be $100.5 million.

Aura Biosciences Announces Oversubscribed $80 Million Financing

Ysios Capital joins Aura Biosciences 80MUSD financing

AELIX Therapeutics presents positive results from randomized placebo-controlled phase I/IIa therapeutic HIV vaccine clinical trial

Results support development of combination strategies based on HTI vaccine to control HIV – without the need for ongoing antiretroviral medication

ONA Therapeutics appoints Mark Throsby to its Board of Directors

Dr. Mark Throsby is a biopharmaceutical executive with extensive research experience and a track record of innovation and execution.

New Data Supports High Reperfusion Rate for Anaconda Biomed’s Mechanical Thrombectomy System

In Vitro Study, Showing Suction Force Correlates with Reperfusion in Hard Clots, Published in Journal of NeuroInterventional Surgery

MedLumics closes upsized EUR 18M (21.7M USD) financing round and appoints new Chairman

Financing to advance optically-guided real-time ablation catheter technology for the treatment of Atrial Fibrillation.

Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease

Sanifit today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead compound SNF472 for the treatment of peripheral arterial disease (PAD) in patients with end-stage kidney disease (ESKD).

CorWave Joins the French Tech 120 Index, a Community That Brings Together the Top French Tech Scale-up Companies

The company develops breakthrough cardiac pumps with the aim of improving the lives of advanced heart failure patients


Subscribe to our weekly newsletter for the latest
updates on life sciences investments.